Where I see patients (2)
My reviews
Selected research
-
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
The oncologist
-
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN
-
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Cancer immunology research
Clinical trials
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combina...
Objective response rate, defined as the proportion of participants with a CR or PR on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.
Recruiting
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III C...
Will be measured using 6 individual Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20) questions that quantify numbness, tingling, and pain in the fingers (or hands) and toes (or feet). For ...
Recruiting
5.0